Emerging Markets Earnings Roundup: BMS, Pfizer (Part 2)
This article was originally published in PharmAsia News
BMS elaborated on its plans to ease out of the emerging market explosion in demand for diabetes treatments as it moves to develop new therapies in immune-oncology. Pfizer saw China revenues rise smartly in the fourth quarter and Lipitor sales standout in emerging markets.
You may also be interested in...
Although the company beat estimates and executed on an ambitious late-stage pipeline, analysts on Pfizer’s earnings call were focused on palbociclib, Prevnar, and the pharma’s plans for its established products business.
MUMBAI - Following studies on the launch of patented brands in the Asia-Pacific market, IMS Health said less than 20 percent of brands perform well if they do not strike significant success within the first six months of their launches
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.